Adc Therapeutics SA Form 4 insider transactions

ADC Therapeutics SA reports an award of restricted stock units to Chief Medical Officer Mohamed Zaki, with vesting conditions tied to employment and time.

ADC Therapeutics SA reports an RSU award to Chief Legal Officer Peter J. Graham, with vesting conditions tied to continued employment and employment status.

ADC Therapeutics SA reports that Chief Financial Officer Jose Carmona was granted 203,700 Restricted Stock Units (RSUs) on June 30, 2026.

ADC Therapeutics SA reports a significant RSU award to CEO Ameet Mallik, vesting in June 2027.

Robert Azelby, a Director at ADC Therapeutics SA, reported transactions involving the acquisition of restricted stock units and the sale of common shares.

Director Ron Squarer reported transactions involving ADC Therapeutics SA common shares, including an annual grant of RSUs and withholding for tax obligations.

Victor Sandor, a Director at ADC Therapeutics SA, reported transactions involving the acquisition of 45,000 restricted stock units and the subsequent sale of 12,600 common shares.

ADC Therapeutics SA reports a Form 4 filing detailing a director's receipt of restricted stock units and subsequent tax withholding.

Peter Hug, a Director at ADC Therapeutics SA, reported transactions involving the acquisition of 45,000 restricted stock units and the subsequent sale of 2,156 common shares.

Jean-Pierre Bizzari, a Director at ADC Therapeutics SA, reported transactions involving restricted stock units and common shares.

Director Timothy Coughlin of ADC Therapeutics SA reported transactions involving common shares and restricted stock units.

Redmile Group, LLC reports significant transactions involving ADC Therapeutics SA common stock, reflecting strategic adjustments in beneficial ownership.

ADC Therapeutics CEO Ameet Mallik disposed of 233,146 common shares to cover tax withholding obligations related to vested restricted share units.

ADC Therapeutics' Chief Medical Officer, Mohamed Zaki, disposed of 41,068 common shares at $3.29 each to satisfy tax withholding obligations.

ADC Therapeutics' Chief Accounting Officer, Lisa Michelle Kallebo, disposed of 7,140 common shares to cover tax withholding obligations related to vested restricted share units.

ADC Therapeutics' Chief Legal Officer, Peter J. Graham, disposed of 49,508 common shares to cover tax withholding obligations related to vested restricted share units.

ADC Therapeutics' Chief Financial Officer, Jose Carmona, reported a disposition of 53,236 common shares for tax withholding related to restricted share unit vesting.

Investment firm Redmile Group, LLC, a 10% owner and director, acquired 3,846,153 pre-funded warrants in ADC Therapeutics SA through a private placement.

ADC Therapeutics SA Director Ron Squarer disposed of 15,184 common shares on June 13, 2025, to cover tax withholding obligations related to restricted share unit vesting.

ADC Therapeutics SA Director Victor Sandor reported the disposition of 12,600 common shares at $3.58 per share to cover tax withholding obligations related to the vesting of restricted share units.

Viviane Monges, a Director at ADC Therapeutics SA, disposed of 2,584 common shares valued at $3.58 per share to satisfy tax withholding obligations related to vested restricted share units.

ADC Therapeutics SA Director Peter Hug reported a routine transaction involving the withholding of 2,144 common shares to cover tax liabilities associated with the vesting of restricted share units.

ADC Therapeutics SA Director Jean-Pierre Bizzari's beneficial ownership of common shares was adjusted due to the withholding of 12,600 shares for tax obligations related to vested restricted share units.

ADC Therapeutics SA Director Robert Azelby reported the disposition of 12,600 common shares at $3.58 per share to cover tax withholding obligations related to vested restricted share units.

Redmile Group, a major institutional investor, has acquired 15,734,267 pre-funded warrants in ADC Therapeutics SA through a private placement, signaling increased confidence.

ADC Therapeutics SA Director Timothy Coughlin was granted 40,000 restricted stock units and 80,000 stock options as part of his compensation, aligning his interests with shareholder value.

ADC Therapeutics SA Director Victor Sandor has been granted 40,000 restricted stock units as part of his annual compensation, aligning his interests with shareholders.

ADC Therapeutics SA Director Robert Azelby was granted 40,000 restricted stock units as part of his annual compensation, increasing his total beneficial ownership to 93,005 common shares.

ADC Therapeutics SA Director Jean-Pierre Bizzari was granted 40,000 restricted stock units as part of his annual compensation, increasing his beneficial ownership to 119,502 common shares.

ADC Therapeutics SA Director Peter Hug has been granted 40,000 restricted stock units (RSUs) as part of his annual compensation, aligning his interests with shareholders.